Compare MTG & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MTG | DFTX |
|---|---|---|
| Founded | 1957 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 2008 | 2020 |
| Metric | MTG | DFTX |
|---|---|---|
| Price | $28.94 | $32.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $30.83 | ★ $72.56 |
| AVG Volume (30 Days) | ★ 2.2M | 1.9M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 8.65 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $1,213,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.04 | N/A |
| P/E Ratio | $17.53 | ★ N/A |
| Revenue Growth | ★ 0.49 | N/A |
| 52 Week Low | $24.69 | $14.62 |
| 52 Week High | $31.89 | $49.70 |
| Indicator | MTG | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 38.72 |
| Support Level | $25.59 | $32.43 |
| Resistance Level | $29.37 | $38.04 |
| Average True Range (ATR) | 0.62 | 1.85 |
| MACD | 0.20 | 0.20 |
| Stochastic Oscillator | 86.84 | 19.79 |
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.